UNSPSC 51321703: Fluvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C24H26FNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4L066368AS, chemically known as (3r,5s)-fluvastatin but generally known as fluvastatin, which bears US NIH Compound Identifier 446155. European Medicines Agency schedules Fluvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07768MIG.

UNSPSC 51321703 Fluvastatin, a Commodity-tier code, represents pharmaceutical products purchased by state and local governments for emergency medical services, state health agencies, and cooperative purchasing alliances. The code reflects medications supplied to fire rescue operations, state pharmacy benefit programs, and multistate procurement consortia seeking generic pharmaceuticals and OTC products through established wholesaler distribution channels. State and local buying under this code centers on emergency life-support medications, generic multi-source pharmaceuticals for health agency programs, and direct-to-manufacturer prescription sourcing initiatives that bypass traditional pharmacy benefit managers.

Activity spans fire rescue procurement at the city level, state health and human services departments, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB No. 26P00188, response due April 8, 2026) for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market set-aside offering a 5 percent bid discount. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs and vendor capacity for outcomes-based contracting outside traditional PBM arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, covering participating state and local facilities across Minnesota and Oregon. Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP representing a multistate consortium model that extends procurement scope across multiple jurisdictions.